Meant to B: B Cells As a Therapeutic Target in Systemic Lupus Erythematosus

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2021 Jun 15

PMID 34128474

Citations 23

Authors

Yemil Atisha-Fregoso

Bahtiyar Toz

Betty Diamond

Affiliations

Soon will be listed here.

Abstract

B cells have a prominent role in the pathogenesis of systemic lupus erythematosus (SLE). They are mediators of inflammation through the production of pathogenic antibodies that augment inflammation and cause direct tissue and cell damage. Multiple therapeutic agents targeting B cells have been successfully used in mouse models of SLE; however, these preclinical studies have led to approval of only one new agent to treat patients with SLE: belimumab, a monoclonal antibody targeting B cell-activating factor (BAFF). Integrating the experience acquired from previous clinical trials with the knowledge generated by new studies about mechanisms of B cell contributions to SLE in specific groups of patients is critical to the development of new treatment strategies that will help to improve outcomes in patients with SLE. In particular, a sharper focus on B cell differentiation to plasma cells is warranted.

Citing Articles

Myricetin exposure reduces PC differentiation in vitro in primary human B cells.

Haque S, Diamond B Mol Med. 2025; 31(1):28.

PMID: 39875809 PMC: 11776280. DOI: 10.1186/s10020-025-01068-x.

EAF2 deficiency attenuates autoimmune disease in mice by modulating B cell activation and apoptosis.

Luan Y, Min Q, Zhang R, Wen Z, Meng X, Hu Z iScience. 2024; 27(11):111220.

PMID: 39555413 PMC: 11565555. DOI: 10.1016/j.isci.2024.111220.

TLR10 expression in unswitched memory B associates with the disease activity of patients with systemic lupus erythematosus.

Zhang L, Yu L, Li Q, Ni M, Dong Q, Bao Y Clin Rheumatol. 2024; 44(1):217-227.

PMID: 39537946 DOI: 10.1007/s10067-024-07231-9.

A rationally designed CD19 monoclonal antibody-triptolide conjugate for the treatment of systemic lupus erythematosus.

Wang L, Yin H, Jiang J, Li Q, Gao C, Li W Acta Pharm Sin B. 2024; 14(10):4560-4576.

PMID: 39525579 PMC: 11544386. DOI: 10.1016/j.apsb.2024.06.024.

Investigating the therapeutic mechanism of Jiedu-Quyu-Ziyin Fang on systemic lupus erythematosus through the ERα-miRNA-TLR7 immune axis.

Zhang Y, Zhang F, Zhang Y, Wang M, Gao Y, Li H Heliyon. 2024; 10(12):e32752.

PMID: 38948043 PMC: 11209013. DOI: 10.1016/j.heliyon.2024.e32752.

References

Klinman D, Steinberg A . Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med. 1987; 165(6):1755-60. PMC: 2188353. DOI: 10.1084/jem.165.6.1755. View

Jenks S, Cashman K, Woodruff M, Lee F, Sanz I . Extrafollicular responses in humans and SLE. Immunol Rev. 2019; 288(1):136-148. PMC: 6422038. DOI: 10.1111/imr.12741. View

Isenberg D, Gordon C, Licu D, Copt S, Rossi C, Wofsy D . Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2014; 74(11):2006-15. PMC: 4680140. DOI: 10.1136/annrheumdis-2013-205067. View

Vinuesa C, Sanz I, Cook M . Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol. 2009; 9(12):845-57. DOI: 10.1038/nri2637. View

Halpern W, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J . Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci. 2006; 91(2):586-99. DOI: 10.1093/toxsci/kfj148. View

Riggs J, Hanna R, Rajan B, Zerrouki K, Karnell J, Sagar D . Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018; 5(1):e000261. PMC: 5890856. DOI: 10.1136/lupus-2018-000261. View

Litinskiy M, Nardelli B, Hilbert D, He B, Schaffer A, Casali P . DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002; 3(9):822-9. PMC: 4621779. DOI: 10.1038/ni829. View

DeGiorgio L, Konstantinov K, Lee S, Hardin J, Volpe B, Diamond B . A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med. 2001; 7(11):1189-93. DOI: 10.1038/nm1101-1189. View

Loberg Haarhaus M, Svenungsson E, Gunnarsson I . Ofatumumab treatment in lupus nephritis patients. Clin Kidney J. 2016; 9(4):552-5. PMC: 4957712. DOI: 10.1093/ckj/sfw022. View

10.

Figgett W, Deliyanti D, Fairfax K, Quah P, Wilkinson-Berka J, Mackay F . Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers. J Autoimmun. 2015; 61:9-16. DOI: 10.1016/j.jaut.2015.04.007. View

11.

Silveira P, Johnson E, Chapman H, Bui T, Tisch R, Serreze D . The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. Eur J Immunol. 2003; 32(12):3657-66. DOI: 10.1002/1521-4141(200212)32:12<3657::AID-IMMU3657>3.0.CO;2-E. View

12.

Cardiel M, Tumlin J, Furie R, Wallace D, Joh T, Linnik M . Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008; 58(8):2470-80. DOI: 10.1002/art.23673. View

13.

Gross J, Dillon S, Mudri S, Johnston J, Littau A, Roque R . TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001; 15(2):289-302. DOI: 10.1016/s1074-7613(01)00183-2. View

14.

Merrill J, Wallace D, Wax S, Kao A, Fraser P, Chang P . Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2017; 70(2):266-276. PMC: 6099253. DOI: 10.1002/art.40360. View

15.

Braun D, Geraldes P, Demengeot J . Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun. 2003; 20(1):15-25. DOI: 10.1016/s0896-8411(02)00109-9. View

16.

Barber M, Clarke A . Socioeconomic consequences of systemic lupus erythematosus. Curr Opin Rheumatol. 2017; 29(5):480-485. DOI: 10.1097/BOR.0000000000000416. View

17.

Mannoor K, Matejuk A, Xu Y, Beardall M, Chen C . Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival. J Immunol. 2012; 188(8):3628-38. DOI: 10.4049/jimmunol.1102859. View

18.

Jacob C, Pricop L, Putterman C, Koss M, Liu Y, Kollaros M . Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol. 2006; 177(4):2671-80. PMC: 2896675. DOI: 10.4049/jimmunol.177.4.2671. View

19.

Garcia-Romo G, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z . Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011; 3(73):73ra20. PMC: 3143837. DOI: 10.1126/scitranslmed.3001201. View

20.

Gomez Mendez L, Cascino M, Garg J, Katsumoto T, Brakeman P, DallEra M . Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. Clin J Am Soc Nephrol. 2018; 13(10):1502-1509. PMC: 6218830. DOI: 10.2215/CJN.01070118. View